96 related articles for article (PubMed ID: 22241371)
1. [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy].
Shibahara H; Ito T; Uematsu N; Imai E; Nishimura D
Gan To Kagaku Ryoho; 2012 Jan; 39(1):143-5. PubMed ID: 22241371
[TBL] [Abstract][Full Text] [Related]
2. A late phase II study of S-1 for metastatic pancreatic cancer.
Okusaka T; Funakoshi A; Furuse J; Boku N; Yamao K; Ohkawa S; Saito H
Cancer Chemother Pharmacol; 2008 Apr; 61(4):615-21. PubMed ID: 17520253
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group).
Strumberg D; Bergmann L; Graeven U; Hanauske A; Lipp R; Schuette J; Schultheis B; Scigalla P; Urrea P; Scheulen ME
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):470-2. PubMed ID: 20557848
[No Abstract] [Full Text] [Related]
4. An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Takezako Y; Morizane C
Oncology; 2005; 68(2-3):171-8. PubMed ID: 16006754
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of mirtazapine for appetite loss and nausea of the cancer patient--from clinical experience in Memorial Sloan-Kettering Cancer Center].
Ito T; Okubo Y; Roth A
Gan To Kagaku Ryoho; 2009 Apr; 36(4):623-6. PubMed ID: 19381036
[TBL] [Abstract][Full Text] [Related]
6. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
Inoue T; Yachida S; Usuki H; Kimura T; Hagiike M; Okano K; Suzuki Y
Ann Surg Oncol; 2012 Sep; 19(9):2937-45. PubMed ID: 22466666
[TBL] [Abstract][Full Text] [Related]
7. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
[TBL] [Abstract][Full Text] [Related]
8. [A case of successful S-1 alternate-day administration for far-advanced remnant gastric cancer].
Kashima Y; Adachi T; Hara N; Sohtome I; Shirasaka T
Gan To Kagaku Ryoho; 2012 Mar; 39(3):469-72. PubMed ID: 22421782
[TBL] [Abstract][Full Text] [Related]
9. [Continuous treatment with S-1, an effective strategy for an older adult with unresectable advanced pancreatic cancer with peritoneal dissemination-a case report].
Okamoto N; Inaba K; Konno H
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1187-9. PubMed ID: 19620815
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
[TBL] [Abstract][Full Text] [Related]
11. Mirtazapine for new daily persistent headache-associated chronic nausea.
Smith JH
Headache; 2015 Jan; 55(1):176-7. PubMed ID: 25262618
[No Abstract] [Full Text] [Related]
12. [S-1 monotherapy for pancreatic cancer].
Okusaka T; Ueno H; Ikeda M; Morizane C
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():207-12. PubMed ID: 16898004
[TBL] [Abstract][Full Text] [Related]
13. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
14. [Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].
Sato I; Ueda N; Kinoshita E; Minato H; Ohno K; Nakaya N; Shimasaki T; Nakajima H; Kosaka T; Motoo Y
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1341-4. PubMed ID: 20647723
[TBL] [Abstract][Full Text] [Related]
15. Intractable nausea and vomiting following Roux-en-Y gastric bypass: role of mirtazapine.
Huerta S; Siddiqui A
Obes Surg; 2006 Oct; 16(10):1399. PubMed ID: 17059757
[No Abstract] [Full Text] [Related]
16. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
[TBL] [Abstract][Full Text] [Related]
17. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
18. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials.
Kobayashi S; Ueno M; Ogawa G; Fukutomi A; Ikeda M; Okusaka T; Sato T; Ito Y; Kadota T; Ioka T; Sugimori K; Sata N; Nakamori S; Shimizu K; Mizuno N; Ishii H; Furuse J
Pancreas; 2021 Aug; 50(7):965-971. PubMed ID: 34629456
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary toxicity by a cytotoxic agent, S-1.
Tada Y; Takiguchi Y; Fujikawa A; Kitamura A; Kurosu K; Hiroshima K; Sakao S; Kasahara Y; Tanabe N; Tatsumi K; Kuriyama T
Intern Med; 2007; 46(15):1243-6. PubMed ID: 17675777
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
